• A spinoff from Ghent University founded by two Ph.D.'s
  • Extensive experience in advanced cardio- and endovascular device-and-procedure modeling
  • Collaborates with academic researchers and clinicians worldwide


  • FEops needs advanced computational modeling tools to help their customers improve the design, safety and efficacy of medical devices tailored to individual patients in need of heart-valve replacement.


  • FEops employs Dassault Systèmes SIMULIA’s Abaqus FEA software, along with proprietary tools, to gain detailed insight into the heart-valve replacement devices with specific patient anatomies, pre-operatively.


  • Dassault Systèmes software has proven highly capable of accurately simulating the methods and complexities of heart-disease treatment.
  • FEops can explore the application of their technologies to a wide range of heart-related fields, getting devices to market faster and helping patients everywhere.

Innovating to Improve Outcomes in Heart Valve Replacement

American Heart Associations’s “2018 Update” on heart disease notes that the number of elderly patients with aortic stenosis is projected to more than double by 2050 in both the United States and Europe. One study (Icelandic AGES-Reykjavik) projects a tripling of that number by 2060. Replacing diseased aortic valves has become a “routine” treatment for patients, either through open-heart surgery or transcatheter aortic valve implantation (TAVI).

TAVI, implemented first in Europe around 2008 and approved by the U.S. FDA in 2011, is being employed in greater numbers of patients every year, particularly for elderly or ill ones. It is much less invasive, as it avoids cardiopulmonary bypass, and requires less time and anesthesia than a major surgical procedure. TAVI involves inserting a catheter, usually through the femoral artery in the thigh, and then threading it up into the heart to secure a replacement valve inside the original one. The new valve is mounted on a dedicated endovascular stent.

There tend to be fewer complications overall with TAVI than with open heart procedures, but problems can still arise: stroke from calcium loosened during the procedure, restricted blood flow, leakage when the new implant doesn’t seal completely, or electrical conduction problems requiring a pacemaker. Innovative researchers have focused on mitigating these types of roadblocks to full patient recovery, making breakthrough progress with realistic simulation.

We have decades of experience using Abaqus specifically for minimally invasive cardiovascular and endovascular devices,” he says. “Abaqus can accurately simulate the complexities of the TAVI procedure and products, which allows us to be very confident in the results.

Matthieu De Beule, Ph.D.
co-founder and CEO, FEops
Abaqus medical FEA case study cover What does Abaqus bring to mechanical simulation in life sciences?

How can it improve patient outcomes?

Download the full, detailed case study.

DLC: Case Study: FEops Direct

  • This field is for validation purposes and should be left unchanged.

How can we help you innovate?

Whether they need software, consulting, or training, companies around the globe partner with us to develop superior products, accelerate their time to market, and lower development costs. What can we do for you?